2.50
Hdl Handle:
http://hdl.handle.net/10541/72638
Title:
Recent developments in the therapy of acromegaly.
Authors:
Paisley, Angela N; Trainer, Peter J
Abstract:
Acromegaly, a condition due to growth hormone hypersecretion usually from a benign pituitary tumour, is associated with significant morbidity and mortality. Disease control leads to normalisation of life expectancy with a reduction in signs and symptoms. Treatment modalities include surgery, radiotherapy and medical management. Surgery is the primary treatment in most of the patients, with success rates of 61-91% reported for those with microadenomas who are operated on by a specialist pituitary surgeon; however, most patients have macroadenomas and, although benefiting from surgery, are not cured and require additional medical therapy. This review will focus on emerging concepts in the medical treatment of acromegaly.
Affiliation:
Department of Endocrinology, Christie Hospital, Manchester, M20 4BX, UK.
Citation:
Recent developments in the therapy of acromegaly. 2006, 15 (3):251-6 Expert Opin Investig Drugs
Journal:
Expert Opinion on Investigational Drugs
Issue Date:
Mar-2006
URI:
http://hdl.handle.net/10541/72638
DOI:
10.1517/13543784.15.3.251
PubMed ID:
16503762
Type:
Article
Language:
en
ISSN:
1744-7658
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorPaisley, Angela N-
dc.contributor.authorTrainer, Peter J-
dc.date.accessioned2009-07-06T15:33:43Z-
dc.date.available2009-07-06T15:33:43Z-
dc.date.issued2006-03-
dc.identifier.citationRecent developments in the therapy of acromegaly. 2006, 15 (3):251-6 Expert Opin Investig Drugsen
dc.identifier.issn1744-7658-
dc.identifier.pmid16503762-
dc.identifier.doi10.1517/13543784.15.3.251-
dc.identifier.urihttp://hdl.handle.net/10541/72638-
dc.description.abstractAcromegaly, a condition due to growth hormone hypersecretion usually from a benign pituitary tumour, is associated with significant morbidity and mortality. Disease control leads to normalisation of life expectancy with a reduction in signs and symptoms. Treatment modalities include surgery, radiotherapy and medical management. Surgery is the primary treatment in most of the patients, with success rates of 61-91% reported for those with microadenomas who are operated on by a specialist pituitary surgeon; however, most patients have macroadenomas and, although benefiting from surgery, are not cured and require additional medical therapy. This review will focus on emerging concepts in the medical treatment of acromegaly.en
dc.language.isoenen
dc.subject.meshAcromegaly-
dc.subject.meshHormone Antagonists-
dc.subject.meshHuman Growth Hormone-
dc.subject.meshHumans-
dc.subject.meshInsulin-Like Growth Factor I-
dc.titleRecent developments in the therapy of acromegaly.en
dc.typeArticleen
dc.contributor.departmentDepartment of Endocrinology, Christie Hospital, Manchester, M20 4BX, UK.en
dc.identifier.journalExpert Opinion on Investigational Drugsen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.